Before Sean was diagnosed and his health began to fail, he was a founder and an executive at a variety of international high technology companies. Sean is now channeling his tech skills in the creation of philanthropic ventures targeted to serving the rare disease community.
One of these ventures, called Rare Funding Team (www.rarefundingteam.com), matches rare disease organisations with digital marketing professionals. Sean observed that many patient organisations are fueled by passion and emotional energy but often lack financial and professional resources. Rare Funding Team provides a platform where critical partnerships can be made in areas of marketing communications, graphics, IT, management and law. Sean is open and ready to collaborate with others for the advancement of the rare disease community so watch this space...
Improving healthcare communications in rare disease and orphan drugs:
Patient community perspective - Benjamin James
1. Benjamin et al. (2017). Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report: https://www.valueinhealthjournal.com/article/S1098-3015(17)30264-4/pdf (accessed 10 January 2020
2. Alliance for Regenerative Medicine (2019). Getting Ready: Recommendations for Timely Access to Advanced Therapy Medicinal products (ATMPs) in Europe: http://alliancerm.org/wp-content/uploads/2019/07/ARM-Market-Access-Report-FINAL.pdf ( accessed 10 January 2020
3. Evaluate (2019). Orphan Drug Report 2019: https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-orphan-drug-report-2019 ( accessed 10 January 2020
4. Lampert et al. (2016). Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161660 ( accessed 10 January 2020)
5. Budych et al. (2012). How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient–physician interaction: https://www.sciencedirect.com/science/article/pii/S0168851012000644?via%3Dihub ( accessed 10 January 2020)
6. AMICULUM (2014). Communication strategies for rare diseases: uncommon opportunities: https://www.comradis.biz/media/1002/communication-strategies-for-rare-diseases-comradis.pdf ( accessed 10 January 2020)
7. Blay et al. (2016). The value of research collaborations and consortia in rare cancers: https://www.sciencedirect.com/science/article/pii/S1098301517302644 ( accessed 10 January 2020)
8. Price et al. (2016). What Can Big Data Offer the Pharmacovigilance of Orphan Drugs? https://www.clinicaltherapeutics.com/article/S0149-2918(16)30847-5/pdf ( accessed 10 January 2020)
9. Polich et al. (2012). Rare disease patient groups as clinical researchers: https://www.sciencedirect.com/science/article/pii/S1359644611003357?via%3Dihub ( accessed 10 January 2020)
10. Hollak et al. (2011). Limitations of drug registires to evaluate orphan medicinal products for the treatment of lysosomal storage disorders: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102605/pdf/1750-1172-6-16.pdf ( accessed 10 January 2020)
11. Giannuzzi et al. (2017). Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen: https://ojrd.biomedcentral.com/articles/10.1186/s13023-017-0617-1 ( accessed 10 January 2020)
Rare Revolution Editor